Zenotech Laboratories

Zenotech Laboratories Equity Growth

The Year-over-Year Equity Growth of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -1.05 %. In the previous year, Year-over-Year Equity Growth was 6.17 % — a change of -117.01% (lower).

Equity Growth

-1.05 %

YoY

-117.01%

Last updated:

Year-over-Year Equity Growth of Zenotech Laboratories is 2026 -1.05 % . Year-over-Year Equity Growth of Zenotech Laboratories was 2025 6.17 % . It decreases by -117.01% lower compared to the previous year.

The Zenotech Laboratories Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2019
-7.42 INR
Jan 1, 2020
27.59 INR
Jan 1, 2021
-2.46 INR
Jan 1, 2022
45.93 INR
Jan 1, 2023
16.46 INR
Jan 1, 2024
10.05 INR
Jan 1, 2025
6.17 INR
Jan 1, 2026
-1.05 INR
The Zenotech Laboratories Equity Growth history
YEAREquity GrowthYoY
-1.05 %-117.01%
6.17 %-38.60%
10.05 %-38.93%
16.46 %-64.15%
45.93 %-1,967.02%
-2.46 %-108.92%
27.59 %-471.60%
-7.42 %-104.53%
163.75 %-480.21%
-43.07 %-39.49%
-71.18 %-75.75%
-293.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

Year-over-Year Equity Growth of Zenotech Laboratories is -1.05 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Zenotech Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories